The analysis begins with a detailed examination of the gene expression and protein structure of KIF20A, highlighting its interaction with critical cellular components that influence key processes such as Golgi membrane transport and mitotic spindle assembly. The primary focus is on the development of specific KIF20A inhibitors, detailing their roles and the challenges encountered in enhancing their efficacy, such as achieving specificity, overcoming tumor resistance, and optimizing delivery systems. Additionally, it delves into the prognostic value of KIF20A across multiple cancer types, emphasizing its role as a novel tumor-associated antigen, which lays the groundwork for the development of targeted peptide vaccines. The therapeutic efficacy of these vaccines as demonstrated in recent clinical trials is discussed. Future directions are proposed, including the integration of precision medicine strategies to personalize treatments and the use of combination therapies to improve outcomes. By concentrating on the significant potential of KIF20A as both a direct target for inhibitors and an antigen in cancer vaccines, this review sets a foundation for future research aimed at harnessing KIF20A for effective cancer treatment.
分析首先详细考察了KIF20A的基因表达与蛋白质结构，重点阐述了其与影响高尔基体膜转运及有丝分裂纺锤体组装等关键过程的细胞组分的相互作用。研究核心聚焦于特异性KIF20A抑制剂的研发，系统阐述了其作用机制及在提升疗效过程中面临的多重挑战，包括实现靶向特异性、克服肿瘤耐药性以及优化递送系统等问题。同时，本文深入探讨了KIF20A在多种癌症类型中的预后价值，强调其作为新型肿瘤相关抗原的重要作用，这为开发靶向多肽疫苗奠定了理论基础。文中进一步讨论了近期临床试验中此类疫苗展现的治疗效果。最后提出未来研究方向，包括整合精准医疗策略以实现个体化治疗，以及采用联合疗法提升临床疗效。通过聚焦KIF20A作为抑制剂直接靶点与癌症疫苗抗原的双重潜力，本综述为未来利用KIF20A开发有效癌症治疗方案的研究奠定了重要基础。
Advancing Cancer Therapy: The Role of KIF20A as a Target for Inhibitor Development and Immunotherapy
肿瘤(癌症)患者之家